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he strength of radionuclide-based proce-
dures is in its ability to measure physiologic
and biochemical processes in various organs.
In cardiology, stress testing originated and
ontinues to evolve from the need to identify
linically significant coronary artery disease
CAD). Nearly 9 million radionuclide myocardial
erfusion imaging studies are performed annually
n the U.S. The majority of the studies are per-
ormed to determine the physiological conse-
uence of luminal narrowing of coronary arteries
and downstream adaptation by the resistance ves-
els and collaterals) in various myocardial regions
f the left ventricle. The advent of localized ther-
pies to specific vessels with bypass surgery or
pecific lesions with percutaneous coronary inter-
ention has extended this indication of radionu-
lide-based myocardial perfusion imaging from
iagnosing CAD to pinpointing areas of myocar-
ial ischemia and guiding interventional therapies
o culprit vascular lesions. Additionally, the physi-
logic significance of CAD burden provides prog-
ostic information in settings such as post-myo-
ardial infarction and pre-operative states.
The introduction of thallium-201 (201Tl) myo-
cardial perfusion imaging in the mid-1970s as an
adjunct to electrocardiography treadmill studies
has evolved into the discipline of nuclear cardiol-
ogy today (1). Advances in both technology and
radiopharmaceuticals over the past 30 years have
contributed significantly to the maturation of the
field. Technological advances include the transi-
tion from planar to single-photon emission com-
puted tomography (SPECT), and recently to high
speed SPECT systems, as well as positron emis-
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vances include a transition from a single 201Tl-
dominated myocardial perfusion tracer, to several
technetium-99m (99mTc)-labeled perfusion trac-
rs, and various PET radiotracers. Currently, nu-
lear cardiology studies represent nearly one-half
f the approximately 20 million nuclear medicine
rocedures performed in the U.S. each year. Since
he introduction of 99mTc-labeled perfusion tracer
in the 1990s, a majority of the laboratories in the
U.S. have switched from 201Tl- to 99mTc-based
myocardial perfusion stress protocols.
Following the discovery of the element Tc and
99mTc in 1938, and the molybdenum-99 (99Mo)/
99mTc generator in the early 1950s, the field of
nuclear medicine has gained tremendous growth.
The subsequent development of the stannous re-
duction “instant kit” technique in the 1970s, con-
tributed significantly to the widespread clinical
use of 99mTc-labeled radiotracers (2). The instant
kit technique allowed the preparation of a variety
of radiopharmaceuticals using a standard format
of adding pertechnetate to a vial containing a
small amount of stannous ion as a reducing agent
and targeting molecule. Advances in 99mTc-
labeled radiopharmaceuticals in concert with its
synergy for producing good quality external imag-
ing of the radiotracer in vivo, were the main fac-
tors contributing to the wide-scale introduction of
99mTc into routine clinical use. Unlike other ra-
dionuclides, 99mTc had the best nuclear properties
for imaging with the Anger camera because the
140-keV gamma emission had satisfactory tissue
penetration (less soft tissue attenuation and scat-
ter), yet the energy was low enough to be colli-
mated easily. In addition, because of its relatively
shorter physical half-life (6 h) compared to Tl (72
h), higher doses of 99mTc-labeled perfusion trac-
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376ers could be injected in patients at a comparable
radiation burden to that of Tl.
The tremendous growth for 99mTc-labeled
radiopharmaceuticals translates to higher de-
mand for 99Mo, which is derived from the irra-
diation of uranium targets in nuclear reactors.
Of the approximately 245 operating research
reactors in the world, 173 are more than 30
years old. Many of the reactors available in the
U.S. are at universities and some of these aging
reactors have been closed (3). Most impor-
tantly, isotope production in the U.S. is limited
to material testing and small quantities of re-
search isotopes rather than for clinical or com-
mercial use. Only 5 of the world’s reactors sup-
port commercial radioisotope supply of 99Mo
erived from the irradiation of uranium targets;
one are located in the U.S. Thus, there are no
acilities in the U.S. that are dedicated to man-
facturing 99Mo for 99Mo/99mTc generators for
clinical or commercial use at the present time.
Realizing the importance of the 99Mo shortage,
he International Atomic Energy Agency met
n Rockville, Maryland, in August 2008 to ad-
ress the nation’s needs for isotopes by enhanc-
ng isotope availability and reliability at a re-
uced cost. While the goals of the meeting
ere laudable, unfortunately, they did not pro-
ide solutions for the ongoing shortage. On the
ther hand, a recent press release from the Eu-
opean Association of Nuclear Medicine has
haracterized the 99Mo shortage situation as a
“chronic disease” rather than a “short term
shortage” (4).
The supply of 99Mo is rather complex with
vulnerability at several points in the chain. Some
of the short term solutions include authorization
to substitute other radiopharmaceuticals for
99mTc, and new transport routes for purifying
99Mo. While an alternative method for Tc chem-
istry can be applied using 94mTc, which is a
ositron emitter and is produced using an en-
iched 94Mo target and a low-energy cyclotron.
However, its short half-life of 52.5 min, the large
number of gamma rays emitted with the positron,
and the expensive cyclotron production method
limit its clinical use. Other clinically available
Food and Drug Administration-approved myocar-
dial perfusion radiotracers in the U.S. include201Tl, 82Rubidium, and 13N-ammonia. Both
82Rubidium and 13N-ammonia require PET tech-
ology for imaging, which is not as readily avail-
ble as SPECT systems. There are approximately
2,000 SPECT cameras compared to only 1,600
ET cameras in the U.S. Thus, PET-based ra-
iotracers cannot, for now, realistically fulfill the
urrent clinical demand for myocardial perfusion
tudies as an alternative to 99mTc-based SPECT
studies.
What about 201Tl? 201Tl is a potassium analog
and is injected as thallous chloride. The radionuclide
element 201Tl itself serves both as the mercury
-rays emitter (for external imaging with SPECT)
nd the myocellular probe (for detecting CAD). In
he case of 99mTc-labeled perfusion tracers, it is the
physicochemical properties of the 99mTc-ligand
omplex that controls the biodistribution, retention,
nd clearance in various organs. The lipophilicity of
he ligand is good for crossing membranes and the
ositive charge is good for directing the movement
cross lipid membranes. 201Tl requires no compli-
ated chemistry for labeling a ligand. 201Tl has a
higher first-pass myocardial extraction fraction than
99mTc-labeled sestamibi or tetrofosmin, providing a
stronger relationship to myocardial blood flow for
identifying CAD. On the other hand, the key ad-
vantage of 99mTc over 201Tl has been primarily
based on its nuclear properties for imaging with the
Anger camera and the sodium iodide crystals used
in most conventional SPECT cameras. However,
with the advent of high speed SPECT cameras that
use different crystals, it may be wise to revisit the
application of 201Tl for myocardial perfusion imag-
ing. 201Tl is cyclotron-produced, readily available,
and is not expensive. Although the radiation burden
to patients (in terms of mSv) may have been some-
what higher than 99mTc when using conventional
PECT systems, recent studies have suggested that
ower doses of 201Tl, in the range of 2.0 to 2.5 mCi,
ould provide excellent image quality (even in pa-
ients with large body habitus) when applied with
igh speed SPECT cameras and at a similar radia-
ion dosimetry to that of 99mTc-based cardiac proto-
ols (5). In addition, although 99mTc has also been
sed for radiolabeling of the targeting tracers for
olecular imaging, the chemistry of attaching 99mTc
to small molecules, such as hormones, enzymes, and
various drugs, can be quite challenging. Transition
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377to other radiotracers, such as iodine-123, may allow
more convenient coupling, because the small radius
of iodine compared to Tc chelate makes radioiodine
better suited for radiolabeling small molecules and
peptides. We believe that in addition to addressing
the problem of shortage, we should reconsider our. Goldman IN, Ramamoorthy N, Adel-
fang P. International Atomic Energy
4
icine (EANM). Pre
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